Open-Label Extension Study to Pioneer Study 6058-SCD-101
← catalyst calendarNCT07401823 · readout in 1,264 d
Sponsored by Fulcrum Therapeutics (industry) · FULC — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-30 | estimated | When the study began enrolling |
| Primary completion | 2030-02-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Intervention
- Drug: Pociredir — also filed as FTX-6058
Primary outcomes
what the primary-completion date above is the date OFNumber of participants reporting Treatment Emergent Adverse Events (TEAEs)
measured Up to Week 196
Number of participants with clinically significant changes in 12-lead Electrocardiogram (ECGs)
measured Up to Week 196
Number of participants with clinically significant changes in Vital signs
measured Up to Week 196
Number of participants with clinically significant changes in Clinical laboratory tests
measured Up to Week 196
Permalink · FULC's whole pipeline · Catalyst calendar · Every registered study · What changed